Skip to main content

Table 2 Comparison of baseline metabolic profile between P/I ratio responders and non-responders

From: The proinsulin/insulin (PI/I) ratio is reduced by postprandial targeting therapy in type 2 diabetes mellitus: a small-scale clinical study

 

Responder

Non responder

n (M/F)

8 (5/3)

7 (5/2)

BMI, kg/m2

23.6 ± 4.2

26.4 ± 4.1

HbA1c(NGSP),%

6.8 ± 0.4

6.9 ± 0.7

HOMA-R

1.85 ± 1.18

3.90 ± 4.58

ISI (Matsuda’s index)

9.30 ± 2.35

6.15 ± 3.23*

Insulinogenic index

1.01 ± 0.69

0.43 ± 0.30*

PI/I ratio

0.08 ± 0.06

0.13 ± 0.15

CPR, nmol/L

0.66 ± 0.33

0.66 ± 0.33

(ng/dL)

(2.0 ± 1.0)

(2.0 ± 1.0)

Total cholesterol, mmol/L

5.18 ± 1.21

5.54 ± 0.59

(mg/dL)

(200 ± 47)

(214 ± 23)

Triglyceride, mmol/L

1.19 ± 0.50

2.32 ± 1.40*

(mg/dL)

(106 ± 45)

(206 ± 124*)

HDL-C, mmol/L

1.73 ± 0.51

1.16 ± 0.31*

(mg/dL)

(67 ± 20)

(45 ± 12*)

  1. Mean ± SD *P < 0.05 vs responder (paired t-test).
  2. BMI, body mass index; HbA1c, hemoglobin A1c; NGSP, National Glycohemoglobin Standardization Program; HOMA-IR, homeostasis model assessment of insulin resistance; ISI, insulin sensitivity index; PI/I ratio, proinsulin/insulin ratio; CPR, C-peptide immunoreactivity; HDL-C, high-density lipoprotein cholesterol; IRI, immunoreactive insulin.